Haemonetics (HAE) 10-Q 7 Nov 24 2025 Q2 Quarterly report Financial data

COVER PAGE

COVER PAGE - shares	6 Months Ended
	Sep. 28, 2024	Nov. 05, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 28, 2024
Document Transition Report	false
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORPORATION
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-29
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2882273
Entity Address, Address Line One	125 Summer Street
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	781
Local Phone Number	848-7100
Title of 12(b) Security	Common stock, $.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,223,887

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net revenues	$ 345,511	$ 318,183	$ 681,683	$ 629,515
Cost of goods sold	158,074	147,673	319,322	291,740
Gross profit	187,437	170,510	362,361	337,775
Operating expenses:
Research and development	16,530	12,665	30,979	25,313
Selling, general and administrative	106,946	115,320	215,194	208,805
Amortization of acquired intangible assets	12,264	7,222	24,735	14,695
Total operating expenses	135,740	135,207	270,908	248,813
Operating income	51,697	35,303	91,453	88,962
Interest and other expense, net	(6,993)	(2,471)	(36)	(4,540)
Income before provision for income taxes	44,704	32,832	91,417	84,422
Provision for income taxes	10,873	7,924	19,213	18,472
Net income	$ 33,831	$ 24,908	$ 72,204	$ 65,950
Basic income (loss) per share (in dollars per share)	$ 0.66	$ 0.49	$ 1.42	$ 1.30
Diluted income (loss) per share (in dollars per share)	$ 0.66	$ 0.48	$ 1.40	$ 1.28
Weighted average shares outstanding
Basic (in shares)	50,898	50,727	50,920	50,634
Diluted (in shares)	51,240	51,396	51,402	51,368
Comprehensive income	$ 41,934	$ 21,721	$ 73,272	$ 63,626

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 28, 2024	Mar. 30, 2024
Current assets:
Cash and cash equivalents	$ 299,283	$ 178,800
Accounts receivable, less allowance for credit losses of $5,912 at September 28, 2024 and $5,695 at March 30, 2024	213,534	206,562
Inventories, net	382,105	317,202
Prepaid expenses and other current assets	60,980	66,339
Total current assets	955,902	768,903
Property, plant and equipment, net	300,478	311,362
Intangible assets, less accumulated amortization of $484,517 at September 28, 2024 and $455,213 at March 30, 2024	487,837	406,117
Goodwill	616,162	565,082
Deferred tax asset	9,083	7,739
Other long-term assets	155,762	136,388
Total assets	2,525,224	2,195,591
Current liabilities:
Notes payable and current maturities of long-term debt	5,434	10,229
Accounts payable	69,242	73,358
Accrued payroll and related costs	49,300	80,708
Other current liabilities	149,970	136,088
Total current liabilities	273,946	300,383
Long-term debt	1,219,523	797,564
Deferred tax liability	62,893	62,644
Other long-term liabilities	90,011	75,041
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,381,127 shares at September 28, 2024 and 50,787,859 shares at March 30, 2024	504	508
Additional paid-in capital	544,375	634,627
Retained earnings	368,536	360,456
Accumulated other comprehensive loss	(34,564)	(35,632)
Total stockholders’ equity	878,851	959,959
Total liabilities and stockholders’ equity	$ 2,525,224	$ 2,195,591

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Sep. 28, 2024	Mar. 30, 2024
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 5,912	$ 5,695
Intangible assets, amortization	$ 484,517	$ 455,213
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	50,381,127	50,787,859
Common stock, shares outstanding (in shares)	50,381,127	50,787,859

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss)/Income
Balance (in shares) at Apr. 01, 2023		50,449,000
Balance at Apr. 01, 2023	$ 817,997	$ 504	$ 594,706	$ 253,168	$ (30,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		40,000
Employee stock purchase plan	2,871		2,871
Exercise of stock options (in shares)		145,000
Exercise of stock options	627	$ 2	5,858	(5,233)
Issuance of restricted stock, net of cancellations (in shares)		140,000
Issuance of restricted stock, net of cancellations	0	$ 2	(2)
Tax withholding on employee equity awards (in shares)		(68,000)
Tax withholding on employee equity awards	(5,773)	$ (1)	(812)	(4,960)
Share-based compensation expense	6,989		6,989
Net income	41,042			41,042
Other comprehensive income (loss)	863				863
Balance (in shares) at Jul. 01, 2023		50,706,000
Balance at Jul. 01, 2023	864,616	$ 507	609,610	284,017	(29,518)
Balance (in shares) at Apr. 01, 2023		50,449,000
Balance at Apr. 01, 2023	817,997	$ 504	594,706	253,168	(30,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	65,950
Balance (in shares) at Sep. 30, 2023		50,740,000
Balance at Sep. 30, 2023	893,660	$ 507	616,960	308,898	(32,705)
Balance (in shares) at Jul. 01, 2023		50,706,000
Balance at Jul. 01, 2023	864,616	$ 507	609,610	284,017	(29,518)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		12,000
Exercise of stock options	692	$ 0	655
Issuance of restricted stock, net of cancellations (in shares)		22,000
Tax withholding on employee equity awards (in shares)		0
Tax withholding on employee equity awards	(75)	$ 0	(11)	(64)
Share-based compensation expense	6,706		6,706
Net income	24,908			24,908
Other comprehensive income (loss)	(3,187)				(3,187)
Balance (in shares) at Sep. 30, 2023		50,740,000
Balance at Sep. 30, 2023	893,660	$ 507	616,960	308,898	(32,705)
Balance (in shares) at Mar. 30, 2024		50,788,000
Balance at Mar. 30, 2024	959,959	$ 508	634,627	360,456	(35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		47,000
Employee stock purchase plan	3,441		3,441
Exercise of stock options (in shares)		73,000
Exercise of stock options	961	$ 1	4,703	(3,743)
Issuance of restricted stock, net of cancellations (in shares)		280,000
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Tax withholding on employee equity awards (in shares)		(35,000)
Tax withholding on employee equity awards	(9,759)	$ 0	(1,315)	(8,444)
Adjustments to additional paid in capital, convertible debt, capped call purchases	88,200		88,200
Share-based compensation expense	7,628		7,628
Net income	38,373			38,373
Other comprehensive income (loss)	(7,035)				(7,035)
Balance (in shares) at Jun. 29, 2024		51,153,000
Balance at Jun. 29, 2024	905,368	$ 512	560,881	386,642	(42,667)
Balance (in shares) at Mar. 30, 2024		50,788,000
Balance at Mar. 30, 2024	959,959	$ 508	634,627	360,456	(35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	72,204
Other comprehensive income (loss)	1,068
Balance (in shares) at Sep. 28, 2024		50,381,000
Balance at Sep. 28, 2024	878,851	$ 504	544,375	368,536	(34,564)
Balance (in shares) at Jun. 29, 2024		51,153,000
Balance at Jun. 29, 2024	905,368	$ 512	560,881	386,642	(42,667)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		5,000
Exercise of stock options	$ 251	$ 0	515	(264)
Shares repurchased (in shares)	(799,000)
Shares repurchased	$ (75,241)	$ (8)	(23,839)	(51,394)
Issuance of restricted stock, net of cancellations (in shares)		23,000
Tax withholding on employee equity awards (in shares)		(1,000)
Tax withholding on employee equity awards	(318)	$ 0	(39)	(279)
Share-based compensation expense	6,857		6,857
Net income	33,831			33,831
Other comprehensive income (loss)	8,103				8,103
Balance (in shares) at Sep. 28, 2024		50,381,000
Balance at Sep. 28, 2024	$ 878,851	$ 504	$ 544,375	$ 368,536	$ (34,564)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:
Net income	$ 72,204	$ 65,950
Non-cash items:
Depreciation and amortization	58,353	46,045
Amortization of fair value inventory step-up	8,978	0
Share-based compensation expense	14,485	13,695
Impairment of intangible assets	2,391	10,419
Gain on repurchase of convertible senior notes, net	(12,600)	0
Inventory reserve adjustment	6,074	2,559
Gains on sales of property, plant and equipment	(14,412)	(444)
Deferred tax benefit	(6,176)	(1,893)
Other non-cash operating activities	4,523	2,111
Change in operating assets and liabilities:
Change in accounts receivable	(1,608)	2,857
Change in inventories	(53,082)	(30,654)
Change in prepaid income taxes	(3,713)	(906)
Change in other assets and other liabilities	(13,890)	(10,291)
Change in accounts payable and accrued expenses	(40,125)	18,762
Net cash provided by operating activities	21,402	118,210
Cash Flows from Investing Activities:
Capital expenditures	(15,089)	(16,794)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(6,754)	(17,523)
Acquisition, net of cash acquired	(150,906)	0
Proceeds from sale of property, plant and equipment	20,551	921
Other investing activities	(10,366)	(7,000)
Net cash used in investing activities	(162,564)	(40,396)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes	700,000	0
Repurchase of convertible senior notes	(185,500)	0
Purchase of capped call related to convertible notes	(88,200)	0
Term loan borrowings	250,000	0
Term loan redemption	(262,500)	0
Payments on revolving facility	50,000	0
Repayment of term loan borrowings	(1,563)	(5,250)
Debt issuance costs	(23,135)	0
Share repurchases	(75,000)	0
Proceeds from employee stock purchase plan	3,441	2,871
Proceeds from exercise of stock options	1,212	1,319
Cash used to net share settle employee equity awards	(9,794)	(5,842)
Other financing activities	(73)	(868)
Net cash provided by (used in) financing activities	258,888	(7,770)
Effect of exchange rates on cash and cash equivalents	2,757	(3,505)
Net Change in Cash and Cash Equivalents	120,483	66,539
Cash and Cash Equivalents at Beginning of Period	178,800	284,466
Cash and Cash Equivalents at End of Period	$ 299,283	$ 351,005

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the “Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the six months ended September 28, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 29, 2025 or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended March 30, 2024. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events as of or for the six months ended September 28, 2024.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Sep. 28, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	2. RECENT ACCOUNTING PRONOUNCEMENTS Standards to be Implemented In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2023-07, Segment Reporting (Topic 280). The new guidance requires public entities to provide expanded disclosures over significant segment expenses and additional disclosures related to the chief operating decision maker. ASC Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new guidance is applicable to Haemonetics beginning with the fiscal 2025 Annual Report on Form 10-K. The Company is currently evaluating the impact to its interim and annual report disclosures. In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740). ASC Update No. 2023-09 requires public entities to provide detailed income tax disclosures, including rate reconciliations and disaggregated income tax payment information, on an annual basis. The updated guidance is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. ASC Update No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K and the Company is currently evaluating the impact to its annual report disclosures.

ACQUISITIONS AND STRATEGIC INVE

ACQUISITIONS AND STRATEGIC INVESTMENTS	6 Months Ended
	Sep. 28, 2024
Investments, All Other Investments [Abstract]
ACQUISITIONS AND STRATEGIC INVESTMENTS	3. ACQUISITIONS AND STRATEGIC INVESTMENTS A cquisitions Attune Medical On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM ® proactive esophageal cooling device, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility. Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment. Purchase Price Allocation The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date. The assessment of fair value is preliminary and is based on information that was available at the time the Condensed Consolidated Financial Statements were prepared. The most significant open item is the accounting for income taxes as the Company is awaiting additional information to complete its assessment of these matters. Measurement period adjustments will be recorded in the period in which they are determined, as if they had been completed at the acquisition date. The finalization of the Company’s purchase accounting assessment could result in changes in the valuation of assets acquired and liabilities assumed, which could be material. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by Topic 805. The preliminary purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the preliminary determination of the fair value of the identifiable assets acquired and liabilities assumed: (In thousands) April 1, 2024 Accounts receivable $ 3,784 Inventories 26,300 Prepaid expenses and other current assets 906 Property, plant and equipment 200 Intangible assets 105,800 Goodwill 70,256 Total assets acquired $ 207,246 Accounts payable 2,260 Accrued payroll and related costs 2,129 Other liabilities 496 Deferred tax liability 26,155 Total liabilities assumed $ 31,040 Net assets acquired $ 176,206 The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset. The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment. Intangible assets acquired consist of the following: (In thousands) Amount Weighted-Average Amortization Period Risk-Adjusted Discount Developed technology $ 96,100 10 years 22.0 % Customer contracts and related relationships 7,800 10 years 21.5 % Trade names 1,900 10 years 21.5 % Total $ 105,800 The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired. Acquisition-Related Costs The Company incurred $9.8 million of acquisition-related costs during the first quarter of fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income. The Company’s condensed consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results. OpSens Inc. On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility. OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire ® , a sensor-guided 3-in-1 guidewire for TAVR procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire ® , a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment. Purchase Price Allocation The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date. The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represe nt the final d etermination of the fair value of the identifiable assets acquired and liabilities assumed: (In thousands) December 12, 2023 Accounts receivable $ 5,960 Inventories 12,075 Prepaid expenses and other current assets 2,062 Property, plant and equipment 3,028 Intangible assets 172,000 Goodwill 79,400 Other long-term assets 4,705 Total assets acquired $ 279,230 Accounts payable 3,251 Accrued payroll and related costs 1,723 Other liabilities 9,746 Deferred tax liability 14,805 Other long-term liabilities 5,853 Total liabilities assumed $ 35,378 Net assets acquired $ 243,852 The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset. The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment. Intangible assets acquired consist of the following: (In thousands) Amount Weighted-Average Amortization Period Risk-Adjusted Discount Developed technology $ 114,900 15 years 20.5 % Customer contracts and related relationships 52,300 15 years 18.9 % Trade names 4,800 15 years 20.5 % Total $ 172,000 The Company recorded a net long-term deferred tax liability of $14.8 million, primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis. Acquisition-Related Costs The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Condensed Consolidated Statements of Income. The Company’s condensed consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results. Strategic Investments As part of the Company’s business development activities, it holds strategic investments in certain entities. As of September 28, 2024, the Compan y has made total investments in Vivasure Medical LTD (“Vivasure”) of €35 million. The investments include both preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties. In addition, the Compan y made certain other strategic investments totaling $10.9 million and $7.6 million during fiscal 2025 and 2024, r espectively. The Company’s strategic investments are classified as other long-term assets on the Company’s Condensed Consolidated Balance Sheets and the Company has not recorded any adjustments to the carrying value of our strategic investments during three and six months ended September 28, 2024 and September 30, 2023.

REVENUE

REVENUE	6 Months Ended
	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	4. REVENUE As of September 28, 2024, the Company had $30.5 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 77% of this amount as revenue within the next twelve months and the remaining balance thereafter. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the Condensed Consolidated Balance Sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of September 28, 2024 and March 30, 2024, the Company had contract liabilities of $36.7 million and $31.2 million, respectively. During the three and six months ended September 28, 2024, the Company recognized $8.5 million and $21.8 million of revenue, respectively, that was included in the above March 30, 2024 contract liability balance. Contract liabilities are classified as other current liabilities on the Condensed Consolidated Balance Sheet. As of September 28, 2024 and March 30, 2024, the Company’s contract assets were immaterial.

RESTRUCTURING

RESTRUCTURING	6 Months Ended
	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING	5. RESTRUCTURING On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business. Operational Excellence Program In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges between $85.0 million and $90.0 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and six months ended September 28, 2024, the Company incurred $1.7 million and $4.1 million , respectively, of restructuring and restructuring related costs under this program. During the three and six months ended September 30, 2023, the Company incurred $2.0 million and $4.2 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this progra m are $81.1 million. Portfolio Rationalization Initiatives In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. In the three and six months ended September 28, 2024, the Company incurred $4.7 million and $9.4 million, respectively, of restructuring and restructuring related costs related to these portfolio rationalization initiatives. The following table summarizes the activ ity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Pr ogram for the six months ended September 28, 2024, which relates to employee severance, other employee costs and inventory reserves: (In thousands) Portfolio Rationalization 2020 Program Total Balance at March 30, 2024 $ 11,309 $ 485 $ 11,794 Costs incurred, net of reversals 9,201 213 9,414 Payments (5,847) (564) (6,411) Balance at September 28, 2024 $ 14,663 $ 134 $ 14,797 The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Cost of goods sold $ 3,765 $ 58 $ 8,131 $ 264 Research and development — — (12) — Selling, general and administrative expenses 1,027 28 1,295 (189) Total $ 4,792 $ 86 $ 9,414 $ 75 As of September 28, 2024, the Company had a restr ucturing liability of $14.8 million , all of which is paya ble within the next twelve months. In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions. The tables below present restructuring and restructuring related costs by reportable segment: Restructuring costs Three Months Ended Six Months Ended (In thousands) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Plasma $ 144 $ 59 $ 207 $ (197) Blood Center 2,393 — 3,556 — Hospital 333 — 630 242 Corporate 1,922 27 5,021 30 Total $ 4,792 $ 86 $ 9,414 $ 75 Restructuring related costs Three Months Ended Six Months Ended (In thousands) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Plasma $ 51 $ 74 $ 226 $ 243 Blood Center 46 28 89 73 Hospital — 98 108 147 Corporate 1,474 1,747 3,666 3,688 Total $ 1,571 $ 1,947 $ 4,089 $ 4,151 Total restructuring and restructuring related costs $ 6,363 $ 2,033 $ 13,503 $ 4,226

INCOME TAXES

INCOME TAXES	6 Months Ended
	Sep. 28, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	6. INCOME TAXES The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs. For the three and six months ended September 28, 2024, the Company reported income tax expense of $10.9 million and $19.2 million, respectively, representing effective tax rates of 24.3% and 21.0%. The effective tax rate for the three months ended September 28, 2024, which includes an immaterial discrete tax benefit. The effective tax rate for the six months ended September 28, 2024 includes $3.6 million of discrete tax benefit, primarily related to stock compensation windfalls. The discrete benefit also includes other items such as provision to return differences. For the three and six months ended September 30, 2023, the Company reported income tax expense of $7.9 million and $18.5 million, respectively, representing effective tax rates of 24.1% and 21.9%, respectively. The effective tax rate for the three months ended September 30, 2023 includes $0.1 million of discrete tax benefit primarily related to stock compensation windfalls. The effective tax rate for the six months ended September 30, 2023 includes $1.3 million of discrete tax benefit primarily related to stock compensation windfalls. The increase in the reported tax rate for the three months ended September 28, 2024, compared to the same period in fiscal 2024, relates primarily to the unfavorable impact of the jurisdictional mix of earnings and non-deductible acquisition-related expenses. The decrease in the reported tax rate for the six months ended September 28, 2024, compared to the same period in fiscal 2024, relates primarily to increased discrete tax benefits year-over-year, partially offset by the unfavorable impact of jurisdictional mix of earnings and non-deductible acquisition-related expenses. On August 26, 2024, the U.S. Tax Court issued a decision in Varian Medical Systems, Inc. v. Commissioner. The decision related to the Tax Cuts and Jobs Act Transition Tax on unrepatriated earnings of applicable foreign subsidiaries. The Company is still evaluating the impact and whether to file a protective refund claim with the U.S. Internal Revenue Service.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Sep. 28, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	7. EARNINGS PER SHARE The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended Six Months Ended (In thousands, except per share amounts) September 28, September 30, September 28, September 30, Basic EPS Net income $ 33,831 $ 24,908 $ 72,204 $ 65,950 Weighted average shares 50,898 50,727 50,920 50,634 Basic income per share $ 0.66 $ 0.49 $ 1.42 $ 1.30 Diluted EPS Net income $ 33,831 $ 24,908 $ 72,204 $ 65,950 Basic weighted average shares 50,898 50,727 50,920 50,634 Net effect of common stock equivalents 342 669 482 734 Diluted weighted average shares 51,240 51,396 51,402 51,368 Diluted income per share $ 0.66 $ 0.48 $ 1.40 $ 1.28 Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the applicable initial conversion prices, and consequently no shares have been included in diluted earnings per share for the co nversion values of both convertible senior notes. For the three and six months ended September 28, 2024, weighted average shares outstanding, assuming dilution, excludes the impact of $0.8 million anti-dilutive shares for both periods. For the three and six months ended September 30, 2023, weighted average shares outstanding, assuming dilution, excludes the impact of $0.7 million and $0.6 million anti-dilutive shares, respectively. Share Repurchase Program In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual tim ing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program. In August 2024, the Company entered into an accelerated share repurchase agreement (“ASR”) with Citibank N.A. (“Citibank”) to repurchase $75.0 million of the Company’s common stock. Pursuant to the terms of the ASR, in August 2024, the Company paid Citibank $75.0 million in cash and received an initial delivery of 0.8 million shares of the Company's common stock based on a closing market price on the New York Stock Exchange on August 28, 2024 of $75.08. This initial delivery of shares represented approximately 80% of the notional amount of the ASR. The ASR was completed in October 2024, subsequent to the end of the second quarter of fiscal 2025, and 0.2 million additional shares were delivered upon settlement. As of September 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.

INVENTORIES

INVENTORIES	6 Months Ended
	Sep. 28, 2024
Inventory Disclosure [Abstract]
INVENTORIES	8. INVENTORIES Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. (In thousands) September 28, March 30, Raw materials $ 110,035 $ 134,150 Work-in-process 36,357 15,488 Finished goods 235,713 167,564 Total inventories $ 382,105 $ 317,202

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Sep. 28, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	9. PROPERTY, PLANT AND EQUIPMENT (In thousands) September 28, March 30, Land $ 3,764 $ 4,130 Building and building improvements 124,264 124,338 Plant equipment and machinery 227,930 204,622 Office equipment and information technology 132,845 129,979 Haemonetics equipment 425,402 456,414 Construction in progress 24,889 39,694 Total 939,094 959,177 Less: accumulated depreciation (638,616) (647,815) Property, plant and equipment, net $ 300,478 $ 311,362 During the three and six months ended September 28, 2024, depreciation expense was $15.0 million and $29.6 million, respectively. During the three and six months ended September 30, 2023, depreciation expense was $13.6 million and $26.9 million, respectively. In the first quarter of fiscal 2025, the Company received $19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $14.1 million that was recorded in selling, general and administrative expenses on the Condensed Consolidated Statements of Income.

LEASES

LEASES	6 Months Ended
	Sep. 28, 2024
Leases [Abstract]
LEASES	10. LEASES Lessor Activity Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consist of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on estimated stand-alone selling prices. Operating lease revenue represents less than 3 percent o f the Company’s total net sales.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	11. GOODWILL AND INTANGIBLE ASSETS The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows: (In thousands) Plasma Blood Center Hospital Total Carrying amount as of March 30, 2024 $ 29,043 $ 33,484 $ 502,555 $ 565,082 Purchase accounting adjustments — — (19,248) (19,248) Acquisitions — — 69,542 69,542 Currency translation — 84 702 786 Carrying amount as of September 28, 2024 $ 29,043 $ 33,568 $ 553,551 $ 616,162 The decrease in goodwill of $19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date. Refer to Note 3, Acquisitions and Strategic Investments, for additional information regarding the acquisitions of OpSens and Attune Medical. The gross carrying amount of intangible assets and the related accumulated amortization as of September 28, 2024 and March 30, 2024 is as follows: (In thousands) Gross Carrying Accumulated Net As of September 28, 2024 Amortizable: Developed technology $ 573,745 $ 199,048 $ 374,697 Customer contracts and related relationships 264,703 194,055 70,648 Capitalized software 84,783 73,160 11,623 Patents and other 27,504 12,326 15,178 Trade names 16,244 5,928 10,316 Total $ 966,979 $ 484,517 $ 482,462 Non-amortizable: In-process software development $ 5,375 Total $ 5,375 (In thousands) Gross Carrying Accumulated Net As of March 30, 2024 Amortizable: Developed technology $ 464,291 $ 178,413 $ 285,878 Customer contracts and related relationships 255,144 190,033 65,111 Capitalized software 84,837 69,491 15,346 Patents and other 24,504 11,820 12,684 Trade names 14,320 5,456 8,864 Total $ 843,096 $ 455,213 $ 387,883 Non-amortizable: In-process research and development $ 13,667 In-process software development 4,567 Total $ 18,234 During fiscal 2025, the Company acquired Attune Medical and recorded $96.1 million of developed technology, $7.8 million of customer contracts and related relationships and $1.9 million of trade name intangibles based on the purchase accounting valuation. Refer to Note 3, Acquisitions and Strategic Investments, for additional information regarding the acquisition. In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization. In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit. Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationship s and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years. During the three and six months ended September 28, 2024, amortization expense was $14.2 million and $28.7 million, respectively. During the three and six months ended September 30, 2023, amortization expense was $9.4 million and $19.2 million, respectively. Future annual amortization expense on intangible assets for the next five years is estimated to be as follows: (In thousands) Remainder of Fiscal 2025 $ 26,135 Fiscal 2026 $ 49,842 Fiscal 2027 $ 47,893 Fiscal 2028 $ 46,121 Fiscal 2029 $ 44,927

NOTES_PAYABLE AND LONG-TERM DEB

NOTES PAYABLE AND LONG-TERM DEBT	6 Months Ended
	Sep. 28, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE AND LONG-TERM DEBT	12. NOTES PAYABLE AND LONG-TERM DEBT Notes payable and long-term debt consisted of the following: (In thousands) September 28, 2024 March 30, 2024 Convertible notes $ 981,513 $ 494,813 Term loan, net of financing fees 242,511 261,971 Revolving credit facility — 50,000 Other borrowings 933 1,009 Less: current portion (5,434) (10,229) Long-term debt $ 1,219,523 $ 797,564 Convertible Senior Notes 2026 Notes In March 2021, the Company issued $500.0 million aggregate principal amount of 0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in Interest and other income (expense), net on the Condensed Consolidated Statements of Income. During the second quarter of fiscal 2025, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of September 28, 2024 and were classified as long-term debt on the Company’s Condensed Consolidated Balance Sheets. As of September 28, 2024, the $300.0 million principal balance was netted down by $2.3 million of remaining debt issuance costs, resulting in a net convertible note payable of $297.7 million. Interest expense related to the 2026 Notes was $0.4 million and $1.0 million for the three and six months ended September 28, 2024, respectively, which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.5%. 2029 Notes On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes and to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below. The Company intends to use the remainder of the proceeds for future cash requirements, which may include additional repurchases of the 2026 Notes from time to time following the offering, or the repayment at maturity of the 2026 Notes. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased. Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances: • During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter; • During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day; • The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price; • Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or • Prior to the related redemption date if the Company calls the 2029 Notes for redemption. On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture. During the second quarter of fiscal 2025, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of September 28, 2024 and were classified as long-term debt on the Company’s consolidated balance sheets. The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest. As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%. As of September 28, 2024, the $700.0 million principal balance was netted down by $16.2 million of remaining debt issuance costs, resulting in a net convertible note payable of $683.8 million. Interest expense related to the 2029 Notes was $5.2 million and $6.9 million for the three and six months ended September 28, 2024, respectively, which includes nominal interest expense and the amortization of the debt issuance costs. Capped Calls In connection with the issuance of the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The Capped Calls each have an initial strike price of approximately $117.12 per share, subject to certain adjustments, which corresponds to the initial conversion price of the 2029 Notes. The Capped Calls have initial cap prices of $180.18 per share, subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes, with such offset subject to a cap based on the cap price. The Capped Calls cover, subject to anti-dilution adjustments, approximately 5.98 million shares of the Company’s common stock. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders' equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the Capped Calls was recorded as a reduction to additional paid-in capital and will not be remeasured. Credit Facilities On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extend their maturity date through June 2025. The amended and restated credit agreement provided for a $280.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together, the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement. On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities will initially bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0.0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity. Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, on up to two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement. The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. During the three and six months ended September 28, 2024, the Company recognized $4.9 million and $12.0 million, respectively, of interest expense and amortization of debt issuance costs related to its credit facilities. At September 28, 2024, $248.4 million was outstanding under the term loan with an effective interest rate of 6.7%, which was netted down by the $5.9 million of remaining debt discount, resulting in a net note payable of $242.5 million. The Company has scheduled principal payments of $6.3 million required during the 12 months following September 28, 2024. There were no outstanding borrowings under the revolving credit facilities at September 28, 2024. The Company also had $19.8 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of September 28, 2024. The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of September 28, 2024. The future aggregate amount of debt maturities are as follows: (In thousands) Remainder of Fiscal 2025 $ 3,198 Fiscal 2026 $ 306,355 Fiscal 2027 $ 6,312 Fiscal 2028 $ 11,003 Fiscal 2029 $ 17,257 Thereafter $ 905,246

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES	6 Months Ended
	Sep. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS The Company manufactures, markets and sells its products globally. During both the three and six months ended September 28, 2024, 25.9% of the Company’s sales were generated outside the U.S. in local currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent, Swiss Franc and Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. Designated Foreign Currency Hedge Contracts All of the Company’s designated foreign currency hedge contracts as of September 28, 2024 and March 30, 2024 were cash flow hedges under ASC 815, Derivatives and Hedging (“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $30.8 million as of September 28, 2024 and $74.0 million as of March 30, 2024. At September 28, 2024, a loss of $1.3 million, net of tax, will be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of September 28, 2024 mature within twelve months. Non-Designated Foreign Currency Contracts The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $38.0 million as of September 28, 2024 and $39.9 million as of March 30, 2024. Interest Rate Swaps Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024. The amendment and extension of the two interest rate swaps did not have a material impact on the Condensed Consolidated Financial Statements. Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps (the “Swaps”) have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of the Swaps are effective and qualify for hedge accounting treatment. The Company held the following interest rate swaps as of September 28, 2024: Hedged Item Original Notional Amount Notional Amount as of September 28, 2024 Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Fair Value Assets (Liabilities) (In thousands) 1-month USD Term SOFR 103,600 103,600 9/27/2024 9/30/2024 4/30/2029 3.32% (634) 1-month USD Term SOFR 102,200 102,200 9/27/2024 9/30/2024 4/30/2029 3.30% (403) Total $ 205,800 $ 205,800 $ (1,037) For the six months ended September 28, 2024, the Company recorded a loss of $2.1 million, net of tax, in accumulated other comprehensive loss to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges. Trade Receivables In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance. The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating se rvices. The Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. The following is a roll forward of the allowance for credit losses: Three Months Ended Six Months Ended (In thousands) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Beginning balance $ 5,719 $ 5,047 $ 5,695 $ 4,932 Credit loss 179 30 216 181 Write-offs 14 (33) 1 (69) Ending balance $ 5,912 $ 5,044 $ 5,912 $ 5,044 Other Fair Value Measurements Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value: • Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Fair Value of Derivative Instruments The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the six months ended September 28, 2024: Derivative Instruments Amount of Gain Recognized Amount of Gain (Loss) Reclassified Location in Amount of Gain Excluded from Location in (In thousands) Designated foreign currency hedge contracts, net of tax $ (1,263) $ (506) Net revenues, COGS and SG&A $ 506 Interest and other expense, net Non-designated foreign currency hedge contracts $ — $ — $ 117 Interest and other expense, net Designated interest rate swaps, net of tax $ (2,053) $ 36 Interest and other expense, net $ — The Company did not have fair value hedges or net investment hedges outstanding as of September 28, 2024 or March 30, 2024. As of September 28, 2024, no material deferred taxes were recognized for designated foreign currency hedges. ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures , by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of September 28, 2024, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments. The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of September 28, 2024 and March 30, 2024: (In thousands) Location in Condensed Consolidated As of As of September 28, 2024 March 30, 2024 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ — $ 1,353 Non-designated foreign currency hedge contracts Other current assets 32 154 Designated interest rate swaps Other current assets 744 1,673 Designated interest rate swaps Other long-term assets — 62 $ 776 $ 3,242 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 624 $ 395 Non-designated foreign currency hedge contracts Other current liabilities 104 536 Designated interest rate swaps Other long-term liabilities 1,781 — $ 2,509 $ 931 Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 28, 2024 and March 30, 2024. As of September 28, 2024 (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 155,290 $ — $ — $ 155,290 Non-designated foreign currency hedge contracts — 32 — 32 Designated interest rate swaps — 744 — 744 $ 155,290 $ 776 $ — $ 156,066 Liabilities Designated foreign currency hedge contracts $ — $ 624 $ — $ 624 Non-designated foreign currency hedge contracts — 104 — 104 Designated interest rate swaps — 1,781 — 1,781 Contingent consideration — — 26,334 26,334 $ — $ 2,509 $ 26,334 $ 28,843 As of March 30, 2024 Level 1 Level 2 Level 3 Total Assets Money market funds $ 43,073 $ — $ — $ 43,073 Designated foreign currency hedge contracts — 1,353 — 1,353 Non-designated foreign currency hedge contracts — 154 — 154 Designated interest rate swaps — 1,735 — 1,735 $ 43,073 $ 3,242 $ — $ 46,315 Liabilities Designated foreign currency hedge contracts $ — $ 395 $ — $ 395 Non-designated foreign currency hedge contracts — 536 — 536 $ — $ 931 $ — $ 931 Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows. Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows. Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy. The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs: Fair Value at Valuation Unobservable (In thousands) September 28, 2024 Technique Input Range Revenue-based payments $ 20,606 Monte Carlo Simulation Model Discount rate 6.3% Projected year of payments 2025 - 2027 Regulatory-based payment $ 4,735 Monte Carlo Simulation Model Discount rate 6.1% Probability of payment 50% Projected year of payment 2026 - 2028 Event-based payment $ 993 Monte Carlo Simulation Model Discount rate 5.8% Projected year of payment 2028 The fair value of contingent consideration associated with the Attune Medical acquisition was $26.3 million at September 28, 2024. As of September 28, 2024, $8.0 million was included in other current liabilities and $18.3 million was included in other long-term liabilities on the Condensed Consolidated Balance Sheets. A reconciliation of the change in the fair value of contingent consideration is included in the following table: (In thousands) Balance at March 30, 2024 $ — Acquisition date fair value of contingent consideration 25,000 Purchase accounting adjustments 300 Change in fair value 1,034 Balance at September 28, 2024 $ 26,334 Other Fair Value Disclosures The fair values of the 2026 Notes and 2029 No tes were $277.7 million and $701.7 million as o f September 28, 2024, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy. The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fa

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	14. COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals. The Company removed the case to the United States District Court for the Northern District Illinois. See Mary Crumpton v. Haemonetics Corporation, Case No. 1:21-cv-1402 . In her complaint, the plaintiff asserts that between June 2017 and August 2018 she donated plasma at a center operated by one of the Company’s customers, that the center required her to scan her fingerprint on a finger scanner that stored her fingerprint to identify her prior to plasma donation, and that the Company’s eQue donor management software sent her biometric information to a Company-owned server to be collected and stored in a manner that violated her rights under the Illinois Biometric Information Privacy Act (“BIPA”). The plaintiff seeks statutory damages, attorneys’ fees and injunctive and equitable relief. In March 2021, the Company moved to dismiss the complaint for lack of personal jurisdiction and concurrently filed a motion to dismiss for failure to state a claim and a motion to stay. In March 2022, the court denied the Company’s motion to dismiss for lack of personal jurisdiction but did not address the merits of the Company’s other positions. In March 2023, the Company filed a second motion to dismiss the complaint, which is pending before the court. During the second quarter of fiscal 2024, the Company entered into a Memorandum of Understanding providing terms that would resolve the litigation and recorded an additional loss contingency related to this matter. In the third quarter of fiscal 2024, the parties requested preliminary court approval of a final settlement agreement, which was granted in February 2024, and the Company recorded an immaterial additional loss contingency related to settlement administration, resulting in an accrual of $8.7 million within Other current liabilities in its consolidated balance sheets. In March 2024, notice of the settlement was mailed to class members and the parties are now awaiting the complete administration of the settlement through the third-party administrator. In the first quarter of fiscal 2025, the Company issued payment of the $8.7 million settlement amount following the court's final approval of the settlement agreement and dismissal of the matter with prejudice. During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics (1:24-cv-00206-CFC). The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages. The Company believes it has valid and meritorious defenses to the complaint and plans to vigorously defend against the complaint. During the first quarter of fiscal 2025, the Company recorded a loss contingency related to this matter, which did not have a material impact on its Condensed Consolidated Financial Statements. Product Recall In August 2023, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. In fiscal 2024, the Company recorded cumulative charges of $6.8 million related to inventory, returns and customer claims associated with this recall. Substantially all outstanding claims have been paid as of September 28, 2024.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	6 Months Ended
	Sep. 28, 2024
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	15. ACCUMULATED OTHER COMPREHENSIVE LOSS The components of Accumulated Other Comprehensive Loss, net of tax, are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain (Loss) on Derivatives Total Balance as of March 30, 2024 $ (38,274) $ 1,748 $ 894 $ (35,632) Other comprehensive income (loss) before reclassifications (1) 4,854 — (3,316) 1,538 Amounts reclassified from accumulated other comprehensive loss (1) — — (470) (470) Net current period other comprehensive income (loss) 4,854 — (3,786) 1,068 Balance as of September 28, 2024 $ (33,420) $ 1,748 $ (2,892) $ (34,564) (1) Presented net of income taxes, the amounts of which are insignificant.

SEGMENT AND ENTERPRISE-WIDE INF

SEGMENT AND ENTERPRISE-WIDE INFORMATION	6 Months Ended
	Sep. 28, 2024
Segment Reporting [Abstract]
SEGMENT AND ENTERPRISE-WIDE INFORMATION	16. SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments, and then by assess i ng whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker. The Company’s reportable and operating segments are as follows: • Plasma • Blood Center • Hospital Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. Selected information by reportable segment is presented below: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Net revenues (1) Plasma $ 138,565 $ 142,643 $ 274,607 $ 282,134 Blood Center 68,804 70,470 135,643 139,639 Hospital 138,384 105,950 272,790 208,378 Net revenues in constant currency 345,753 319,063 683,040 630,151 Effect of exchange rates (242) (880) (1,357) (636) Net revenues $ 345,511 $ 318,183 $ 681,683 $ 629,515 (1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation. Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Segment operating income Plasma $ 69,728 $ 78,042 $ 135,565 $ 153,740 Blood Center 27,167 27,307 49,789 53,590 Hospital 59,705 41,834 113,596 82,777 Segment operating income 156,600 147,183 298,950 290,107 Corporate expenses (1) (74,407) (75,750) (144,387) (151,059) Effect of exchange rates 1,312 (3,091) (37) (478) Amortization of acquired intangible assets (12,264) (7,222) (24,735) (14,695) Amortization of fair value inventory step-up (3,739) — (8,978) — Integration and transaction costs (882) (1,784) (13,205) (2,899) Restructuring costs (4,792) (86) (9,414) (75) Restructuring related costs (1,571) (1,947) (4,089) (4,151) Digital transformation costs (4,858) (3,592) (11,203) (7,297) PCS2 related charges — (552) — (411) MDR and IVDR costs (991) (1,988) (2,117) (3,154) Litigation-related charges (320) (5,449) (1,075) (6,507) Impairment of intangible assets (2,391) (10,419) (2,391) (10,419) Gain on sale of property, plant and equipment — — 14,134 — Operating income $ 51,697 $ 35,303 $ 91,453 $ 88,962 (1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions. Net revenues by business unit are as follows: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Plasma $ 138,561 $ 142,794 $ 274,471 $ 282,415 Apheresis 54,332 54,973 103,426 104,139 Whole Blood 14,196 14,683 31,347 34,723 Blood Center 68,528 69,656 134,773 138,862 Interventional Technologies (1) 61,923 38,541 124,967 76,161 Blood Management Technologies (2) 76,499 67,192 147,472 132,077 Hospital 138,422 105,733 272,439 208,238 Net revenues (3) $ 345,511 $ 318,183 $ 681,683 $ 629,515 (1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit. (2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. (3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation. Net revenues generated in the Company’s principle operating regions on a reported basis are as follows: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, United States $ 256,061 $ 236,345 $ 504,963 $ 473,418 Japan 16,424 15,011 30,129 26,784 Europe 41,991 38,666 89,216 78,053 Rest of Asia 25,768 27,735 45,551 49,775 Other 5,267 426 11,824 1,485 Net revenues $ 345,511 $ 318,183 $ 681,683 $ 629,515

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Sep. 28, 2024	Jun. 29, 2024	Sep. 30, 2023	Jul. 01, 2023	Sep. 28, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income	$ 33,831	$ 38,373	$ 24,908	$ 41,042	$ 72,204	$ 65,950

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 28, 2024
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Josep L. Llorens [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the three months ended September 28, 2024, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.

ACQUISITIONS AND STRATEGIC IN_2

ACQUISITIONS AND STRATEGIC INVESTMENTS (Tables)	6 Months Ended
	Sep. 28, 2024
Investments, All Other Investments [Abstract]
Schedule of Business Acquisitions, by Acquisition	The preliminary purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the preliminary determination of the fair value of the identifiable assets acquired and liabilities assumed: (In thousands) April 1, 2024 Accounts receivable $ 3,784 Inventories 26,300 Prepaid expenses and other current assets 906 Property, plant and equipment 200 Intangible assets 105,800 Goodwill 70,256 Total assets acquired $ 207,246 Accounts payable 2,260 Accrued payroll and related costs 2,129 Other liabilities 496 Deferred tax liability 26,155 Total liabilities assumed $ 31,040 Net assets acquired $ 176,206 The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represe nt the final d etermination of the fair value of the identifiable assets acquired and liabilities assumed: (In thousands) December 12, 2023 Accounts receivable $ 5,960 Inventories 12,075 Prepaid expenses and other current assets 2,062 Property, plant and equipment 3,028 Intangible assets 172,000 Goodwill 79,400 Other long-term assets 4,705 Total assets acquired $ 279,230 Accounts payable 3,251 Accrued payroll and related costs 1,723 Other liabilities 9,746 Deferred tax liability 14,805 Other long-term liabilities 5,853 Total liabilities assumed $ 35,378 Net assets acquired $ 243,852
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination	Intangible assets acquired consist of the following: (In thousands) Amount Weighted-Average Amortization Period Risk-Adjusted Discount Developed technology $ 96,100 10 years 22.0 % Customer contracts and related relationships 7,800 10 years 21.5 % Trade names 1,900 10 years 21.5 % Total $ 105,800 Intangible assets acquired consist of the following: (In thousands) Amount Weighted-Average Amortization Period Risk-Adjusted Discount Developed technology $ 114,900 15 years 20.5 % Customer contracts and related relationships 52,300 15 years 18.9 % Trade names 4,800 15 years 20.5 % Total $ 172,000

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	6 Months Ended
	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following table summarizes the activ ity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Pr ogram for the six months ended September 28, 2024, which relates to employee severance, other employee costs and inventory reserves: (In thousands) Portfolio Rationalization 2020 Program Total Balance at March 30, 2024 $ 11,309 $ 485 $ 11,794 Costs incurred, net of reversals 9,201 213 9,414 Payments (5,847) (564) (6,411) Balance at September 28, 2024 $ 14,663 $ 134 $ 14,797
Schedule of Restructuring and Related Costs	The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Cost of goods sold $ 3,765 $ 58 $ 8,131 $ 264 Research and development — — (12) — Selling, general and administrative expenses 1,027 28 1,295 (189) Total $ 4,792 $ 86 $ 9,414 $ 75 The tables below present restructuring and restructuring related costs by reportable segment: Restructuring costs Three Months Ended Six Months Ended (In thousands) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Plasma $ 144 $ 59 $ 207 $ (197) Blood Center 2,393 — 3,556 — Hospital 333 — 630 242 Corporate 1,922 27 5,021 30 Total $ 4,792 $ 86 $ 9,414 $ 75 Restructuring related costs Three Months Ended Six Months Ended (In thousands) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Plasma $ 51 $ 74 $ 226 $ 243 Blood Center 46 28 89 73 Hospital — 98 108 147 Corporate 1,474 1,747 3,666 3,688 Total $ 1,571 $ 1,947 $ 4,089 $ 4,151 Total restructuring and restructuring related costs $ 6,363 $ 2,033 $ 13,503 $ 4,226

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Sep. 28, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended Six Months Ended (In thousands, except per share amounts) September 28, September 30, September 28, September 30, Basic EPS Net income $ 33,831 $ 24,908 $ 72,204 $ 65,950 Weighted average shares 50,898 50,727 50,920 50,634 Basic income per share $ 0.66 $ 0.49 $ 1.42 $ 1.30 Diluted EPS Net income $ 33,831 $ 24,908 $ 72,204 $ 65,950 Basic weighted average shares 50,898 50,727 50,920 50,634 Net effect of common stock equivalents 342 669 482 734 Diluted weighted average shares 51,240 51,396 51,402 51,368 Diluted income per share $ 0.66 $ 0.48 $ 1.40 $ 1.28

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Sep. 28, 2024
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. (In thousands) September 28, March 30, Raw materials $ 110,035 $ 134,150 Work-in-process 36,357 15,488 Finished goods 235,713 167,564 Total inventories $ 382,105 $ 317,202

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	6 Months Ended
	Sep. 28, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	(In thousands) September 28, March 30, Land $ 3,764 $ 4,130 Building and building improvements 124,264 124,338 Plant equipment and machinery 227,930 204,622 Office equipment and information technology 132,845 129,979 Haemonetics equipment 425,402 456,414 Construction in progress 24,889 39,694 Total 939,094 959,177 Less: accumulated depreciation (638,616) (647,815) Property, plant and equipment, net $ 300,478 $ 311,362

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
	Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by operating segment for fiscal 2025 are as follows: (In thousands) Plasma Blood Center Hospital Total Carrying amount as of March 30, 2024 $ 29,043 $ 33,484 $ 502,555 $ 565,082 Purchase accounting adjustments — — (19,248) (19,248) Acquisitions — — 69,542 69,542 Currency translation — 84 702 786 Carrying amount as of September 28, 2024 $ 29,043 $ 33,568 $ 553,551 $ 616,162
Schedule of Finite-Lived Intangible Assets	The gross carrying amount of intangible assets and the related accumulated amortization as of September 28, 2024 and March 30, 2024 is as follows: (In thousands) Gross Carrying Accumulated Net As of September 28, 2024 Amortizable: Developed technology $ 573,745 $ 199,048 $ 374,697 Customer contracts and related relationships 264,703 194,055 70,648 Capitalized software 84,783 73,160 11,623 Patents and other 27,504 12,326 15,178 Trade names 16,244 5,928 10,316 Total $ 966,979 $ 484,517 $ 482,462 Non-amortizable: In-process software development $ 5,375 Total $ 5,375 (In thousands) Gross Carrying Accumulated Net As of March 30, 2024 Amortizable: Developed technology $ 464,291 $ 178,413 $ 285,878 Customer contracts and related relationships 255,144 190,033 65,111 Capitalized software 84,837 69,491 15,346 Patents and other 24,504 11,820 12,684 Trade names 14,320 5,456 8,864 Total $ 843,096 $ 455,213 $ 387,883 Non-amortizable: In-process research and development $ 13,667 In-process software development 4,567 Total $ 18,234
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Future annual amortization expense on intangible assets for the next five years is estimated to be as follows: (In thousands) Remainder of Fiscal 2025 $ 26,135 Fiscal 2026 $ 49,842 Fiscal 2027 $ 47,893 Fiscal 2028 $ 46,121 Fiscal 2029 $ 44,927

Debt (Tables)

Debt (Tables)	6 Months Ended
	Sep. 28, 2024
Debt Disclosure [Abstract]
Schedule of Debt	Notes payable and long-term debt consisted of the following: (In thousands) September 28, 2024 March 30, 2024 Convertible notes $ 981,513 $ 494,813 Term loan, net of financing fees 242,511 261,971 Revolving credit facility — 50,000 Other borrowings 933 1,009 Less: current portion (5,434) (10,229) Long-term debt $ 1,219,523 $ 797,564
Schedule of Maturities of Long-Term Debt	The future aggregate amount of debt maturities are as follows: (In thousands) Remainder of Fiscal 2025 $ 3,198 Fiscal 2026 $ 306,355 Fiscal 2027 $ 6,312 Fiscal 2028 $ 11,003 Fiscal 2029 $ 17,257 Thereafter $ 905,246

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Tables)	6 Months Ended
	Sep. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Interest Rate Swaps	The Company held the following interest rate swaps as of September 28, 2024: Hedged Item Original Notional Amount Notional Amount as of September 28, 2024 Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Fair Value Assets (Liabilities) (In thousands) 1-month USD Term SOFR 103,600 103,600 9/27/2024 9/30/2024 4/30/2029 3.32% (634) 1-month USD Term SOFR 102,200 102,200 9/27/2024 9/30/2024 4/30/2029 3.30% (403) Total $ 205,800 $ 205,800 $ (1,037)
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the six months ended September 28, 2024: Derivative Instruments Amount of Gain Recognized Amount of Gain (Loss) Reclassified Location in Amount of Gain Excluded from Location in (In thousands) Designated foreign currency hedge contracts, net of tax $ (1,263) $ (506) Net revenues, COGS and SG&A $ 506 Interest and other expense, net Non-designated foreign currency hedge contracts $ — $ — $ 117 Interest and other expense, net Designated interest rate swaps, net of tax $ (2,053) $ 36 Interest and other expense, net $ —
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of the Company’s derivative instruments as they appear in its Condensed Consolidated Balance Sheets as of September 28, 2024 and March 30, 2024: (In thousands) Location in Condensed Consolidated As of As of September 28, 2024 March 30, 2024 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ — $ 1,353 Non-designated foreign currency hedge contracts Other current assets 32 154 Designated interest rate swaps Other current assets 744 1,673 Designated interest rate swaps Other long-term assets — 62 $ 776 $ 3,242 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 624 $ 395 Non-designated foreign currency hedge contracts Other current liabilities 104 536 Designated interest rate swaps Other long-term liabilities 1,781 — $ 2,509 $ 931
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 28, 2024 and March 30, 2024. As of September 28, 2024 (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 155,290 $ — $ — $ 155,290 Non-designated foreign currency hedge contracts — 32 — 32 Designated interest rate swaps — 744 — 744 $ 155,290 $ 776 $ — $ 156,066 Liabilities Designated foreign currency hedge contracts $ — $ 624 $ — $ 624 Non-designated foreign currency hedge contracts — 104 — 104 Designated interest rate swaps — 1,781 — 1,781 Contingent consideration — — 26,334 26,334 $ — $ 2,509 $ 26,334 $ 28,843 As of March 30, 2024 Level 1 Level 2 Level 3 Total Assets Money market funds $ 43,073 $ — $ — $ 43,073 Designated foreign currency hedge contracts — 1,353 — 1,353 Non-designated foreign currency hedge contracts — 154 — 154 Designated interest rate swaps — 1,735 — 1,735 $ 43,073 $ 3,242 $ — $ 46,315 Liabilities Designated foreign currency hedge contracts $ — $ 395 $ — $ 395 Non-designated foreign currency hedge contracts — 536 — 536 $ — $ 931 $ — $ 931 The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs: Fair Value at Valuation Unobservable (In thousands) September 28, 2024 Technique Input Range Revenue-based payments $ 20,606 Monte Carlo Simulation Model Discount rate 6.3% Projected year of payments 2025 - 2027 Regulatory-based payment $ 4,735 Monte Carlo Simulation Model Discount rate 6.1% Probability of payment 50% Projected year of payment 2026 - 2028 Event-based payment $ 993 Monte Carlo Simulation Model Discount rate 5.8% Projected year of payment 2028
Accounts Receivable, Allowance for Credit Loss	The following is a roll forward of the allowance for credit losses: Three Months Ended Six Months Ended (In thousands) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Beginning balance $ 5,719 $ 5,047 $ 5,695 $ 4,932 Credit loss 179 30 216 181 Write-offs 14 (33) 1 (69) Ending balance $ 5,912 $ 5,044 $ 5,912 $ 5,044
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	A reconciliation of the change in the fair value of contingent consideration is included in the following table: (In thousands) Balance at March 30, 2024 $ — Acquisition date fair value of contingent consideration 25,000 Purchase accounting adjustments 300 Change in fair value 1,034 Balance at September 28, 2024 $ 26,334

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	6 Months Ended
	Sep. 28, 2024
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of Accumulated Other Comprehensive Loss, net of tax, are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain (Loss) on Derivatives Total Balance as of March 30, 2024 $ (38,274) $ 1,748 $ 894 $ (35,632) Other comprehensive income (loss) before reclassifications (1) 4,854 — (3,316) 1,538 Amounts reclassified from accumulated other comprehensive loss (1) — — (470) (470) Net current period other comprehensive income (loss) 4,854 — (3,786) 1,068 Balance as of September 28, 2024 $ (33,420) $ 1,748 $ (2,892) $ (34,564) (1) Presented net of income taxes, the amounts of which are insignificant.

SEGMENT AND ENTERPRISE-WIDE I_2

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)	6 Months Ended
	Sep. 28, 2024
Segment Reporting [Abstract]
Selected Information by Business Segment	Selected information by reportable segment is presented below: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Net revenues (1) Plasma $ 138,565 $ 142,643 $ 274,607 $ 282,134 Blood Center 68,804 70,470 135,643 139,639 Hospital 138,384 105,950 272,790 208,378 Net revenues in constant currency 345,753 319,063 683,040 630,151 Effect of exchange rates (242) (880) (1,357) (636) Net revenues $ 345,511 $ 318,183 $ 681,683 $ 629,515 (1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation. Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Segment operating income Plasma $ 69,728 $ 78,042 $ 135,565 $ 153,740 Blood Center 27,167 27,307 49,789 53,590 Hospital 59,705 41,834 113,596 82,777 Segment operating income 156,600 147,183 298,950 290,107 Corporate expenses (1) (74,407) (75,750) (144,387) (151,059) Effect of exchange rates 1,312 (3,091) (37) (478) Amortization of acquired intangible assets (12,264) (7,222) (24,735) (14,695) Amortization of fair value inventory step-up (3,739) — (8,978) — Integration and transaction costs (882) (1,784) (13,205) (2,899) Restructuring costs (4,792) (86) (9,414) (75) Restructuring related costs (1,571) (1,947) (4,089) (4,151) Digital transformation costs (4,858) (3,592) (11,203) (7,297) PCS2 related charges — (552) — (411) MDR and IVDR costs (991) (1,988) (2,117) (3,154) Litigation-related charges (320) (5,449) (1,075) (6,507) Impairment of intangible assets (2,391) (10,419) (2,391) (10,419) Gain on sale of property, plant and equipment — — 14,134 — Operating income $ 51,697 $ 35,303 $ 91,453 $ 88,962 (1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Business Unit and Geographic Regions	Net revenues by business unit are as follows: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, Plasma $ 138,561 $ 142,794 $ 274,471 $ 282,415 Apheresis 54,332 54,973 103,426 104,139 Whole Blood 14,196 14,683 31,347 34,723 Blood Center 68,528 69,656 134,773 138,862 Interventional Technologies (1) 61,923 38,541 124,967 76,161 Blood Management Technologies (2) 76,499 67,192 147,472 132,077 Hospital 138,422 105,733 272,439 208,238 Net revenues (3) $ 345,511 $ 318,183 $ 681,683 $ 629,515 (1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit. (2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. (3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation. Net revenues generated in the Company’s principle operating regions on a reported basis are as follows: Three Months Ended Six Months Ended (In thousands) September 28, September 30, September 28, September 30, United States $ 256,061 $ 236,345 $ 504,963 $ 473,418 Japan 16,424 15,011 30,129 26,784 Europe 41,991 38,666 89,216 78,053 Rest of Asia 25,768 27,735 45,551 49,775 Other 5,267 426 11,824 1,485 Net revenues $ 345,511 $ 318,183 $ 681,683 $ 629,515

ACQUISITIONS AND STRATEGIC IN_3

ACQUISITIONS AND STRATEGIC INVESTMENTS - Strategic Investments (Details) $ in Thousands, € in Millions	3 Months Ended		6 Months Ended
	Sep. 28, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 28, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 28, 2024 EUR (€)
Schedule of Investments [Line Items]
Payment to acquire investment	$ 10,900			$ 7,600
Gain (loss) on investments	$ 0	$ 0	$ 0	$ 0
Vivasure Medical LTD
Schedule of Investments [Line Items]
Investment | €					€ 35

ACQUISITIONS AND STRATEGIC IN_4

ACQUISITIONS AND STRATEGIC INVESTMENTS - Narrative (Details) - USD ($) $ in Thousands			6 Months Ended
	Apr. 01, 2024	Dec. 12, 2023	Sep. 28, 2024	Sep. 30, 2023
Business Acquisition [Line Items]
Payments to acquire businesses, net of cash acquired			$ 150,906	$ 0
OpSens, Inc.
Business Acquisition [Line Items]
Upfront payment		$ 254,500
Payments to acquire businesses, net of cash acquired		243,900
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents		10,600
OpSens, Inc. | Selling, general and administrative expenses
Business Acquisition [Line Items]
Legal and professional fees		$ 6,600
Attune Medical
Business Acquisition [Line Items]
Total consideration	$ 187,700
Upfront payment	162,000
Payments to acquire businesses, net of cash acquired	150,500
Contingent consideration	25,300
Business combination, estimated working capital adjustment	400
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents	$ 11,500
Attune Medical | Selling, general and administrative expenses
Business Acquisition [Line Items]
Legal and professional fees			$ 9,800

ACQUISITIONS AND STRATEGIC IN_5

ACQUISITIONS AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Apr. 01, 2024	Dec. 12, 2023	Sep. 28, 2024	Mar. 30, 2024
Business Acquisition [Line Items]
Goodwill			$ 616,162	$ 565,082
Attune Medical
Business Acquisition [Line Items]
Accounts receivable	$ 3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256
Total assets acquired	207,246
Accounts payable	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155
Total liabilities assumed	31,040
Net assets acquired	176,206
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents	11,500
Attune Medical | Developed technology
Business Acquisition [Line Items]
Acquired intangibles	$ 96,100
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	22%
Attune Medical | Customer contracts and related relationships
Business Acquisition [Line Items]
Acquired intangibles	$ 7,800
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%
Attune Medical | Trade names
Business Acquisition [Line Items]
Acquired intangibles	$ 1,900
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%
OpSens, Inc.
Business Acquisition [Line Items]
Accounts receivable		$ 5,960
Inventories		12,075
Prepaid expenses and other current assets		2,062
Property, plant and equipment		3,028
Intangible assets		172,000
Goodwill		79,400
Other long-term assets		4,705
Total assets acquired		279,230
Accounts payable		3,251
Accrued payroll and related costs		1,723
Other liabilities		9,746
Deferred tax liability		14,805
Other long-term liabilities		5,853
Total liabilities assumed		35,378
Net assets acquired		243,852
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents		10,600
OpSens, Inc. | Developed technology
Business Acquisition [Line Items]
Acquired intangibles		$ 114,900
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%
OpSens, Inc. | Customer contracts and related relationships
Business Acquisition [Line Items]
Acquired intangibles		$ 52,300
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		18.90%
OpSens, Inc. | Trade names
Business Acquisition [Line Items]
Acquired intangibles		$ 4,800
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 28, 2024	Sep. 28, 2024	Mar. 30, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation amount	$ 30.5	$ 30.5
Performance obligation percent	77%	77%
Contract liabilities	$ 36.7	$ 36.7	$ 31.2
Revenue recognized	$ 8.5	$ 21.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-06-28
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction	12 months	12 months

RESTRUCTURING (Narrative) (Deta

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Mar. 30, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring and Restructuring Related Costs	$ 6,363	$ 2,033	$ 13,503	$ 4,226
Restructuring liability	14,797		14,797		$ 11,794
2020 Program
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost	1,700		4,100
Restructuring and Restructuring Related Costs		$ 2,000		$ 4,200
Cumulative costs to date	81,100		81,100
Restructuring liability	134		134		485
2020 Program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected cost	85,000		85,000
2020 Program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected cost	90,000		90,000
Portfolio Rationalization
Restructuring Cost and Reserve [Line Items]
Restructuring and Restructuring Related Costs	4,700		9,400
Restructuring liability	$ 14,663		$ 14,663		$ 11,309

RESTRUCTURING (Schedule of Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Reserve [Roll Forward]
Balance at March 30, 2024			$ 11,794
Costs incurred, net of reversals	$ 4,792	$ 86	9,414	$ 75
Payments			(6,411)
Balance at September 28, 2024	14,797		14,797
Portfolio Rationalization
Restructuring Reserve [Roll Forward]
Balance at March 30, 2024			11,309
Costs incurred, net of reversals			9,201
Payments			(5,847)
Balance at September 28, 2024	14,663		14,663
2020 Program
Restructuring Reserve [Roll Forward]
Balance at March 30, 2024			485
Costs incurred, net of reversals			213
Payments			(564)
Balance at September 28, 2024	$ 134		$ 134

RESTRUCTURING (Schedule of Re_2

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 4,792	$ 86	$ 9,414	$ 75
Restructuring related costs	1,571	1,947	4,089	4,151
Restructuring and Restructuring Related Costs	6,363	2,033	13,503	4,226
Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	144	59	207	(197)
Restructuring related costs	51	74	226	243
Blood Center
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,393	0	3,556	0
Restructuring related costs	46	28	89	73
Hospital
Restructuring Cost and Reserve [Line Items]
Restructuring costs	333	0	630	242
Restructuring related costs	0	98	108	147
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,922	27	5,021	30
Restructuring related costs	1,474	1,747	3,666	3,688
Cost of goods sold
Restructuring Cost and Reserve [Line Items]
Restructuring costs	3,765	58	8,131	264
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	0	(12)	0
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,027	$ 28	$ 1,295	$ (189)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Income Tax Contingency [Line Items]
Provision for income taxes	$ 10,873	$ 7,924	$ 19,213	$ 18,472
Reported tax rate	24.30%	24.10%	21%	21.90%
Stock Compensation Windfalls
Income Tax Contingency [Line Items]
Discrete tax benefit (expense)	$ (3,600)	$ (100)		$ (1,300)

EARNINGS PER SHARE (Schedule of

EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Sep. 28, 2024	Jun. 29, 2024	Sep. 30, 2023	Jul. 01, 2023	Sep. 28, 2024	Sep. 30, 2023
Basic EPS
Net income	$ 33,831	$ 38,373	$ 24,908	$ 41,042	$ 72,204	$ 65,950
Weighted average shares (in shares)	50,898,000		50,727,000		50,920,000	50,634,000
Basic income (loss) per share (in dollars per share)	$ 0.66		$ 0.49		$ 1.42	$ 1.30
Diluted EPS
Net income	$ 33,831	$ 38,373	$ 24,908	$ 41,042	$ 72,204	$ 65,950
Net effect of common stock equivalents (in shares)	342,000		669,000		482,000	734,000
Diluted weighted average shares (in shares)	51,240,000		51,396,000		51,402,000	51,368,000
Diluted income (loss) per share (in dollars per share)	$ 0.66		$ 0.48		$ 1.40	$ 1.28
Anti-dilutive shares (in shares)	800,000		700,000		800,000	600,000

EARNINGS PER SHARE (Share Repur

EARNINGS PER SHARE (Share Repurchase Program) (Details) shares in Thousands, $ in Thousands			3 Months Ended
	Nov. 01, 2024 shares	Aug. 28, 2024 USD ($) $ / shares shares	Sep. 28, 2024 USD ($) shares	Aug. 31, 2022 USD ($)
Share Repurchase Program [Line Items]
Share repurchase plan, authorized amount				$ 300,000
Accelerated share repurchases, settlement (payment) or receipt		$ 75,000
Shares repurchased (in shares) | shares			799
Remaining authorized amount			$ 150,000
2024 Accelerated Share Repurchase Program
Share Repurchase Program [Line Items]
Accelerated share repurchases, settlement (payment) or receipt		$ 75,000
Shares repurchased (in shares) | shares		800
Accelerated share repurchases, initial price paid per share (in CAD per share) | $ / shares		$ 75.08
Accelerated share repurchases, initial delivery percentage of notional amount (as a percent)		80%
2024 Accelerated Share Repurchase Program | Subsequent Event
Share Repurchase Program [Line Items]
Shares repurchased (in shares) | shares	200

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Mar. 30, 2024
Inventory Disclosure [Abstract]
Raw materials	$ 110,035	$ 134,150
Work-in-process	36,357	15,488
Finished goods	235,713	167,564
Inventories, net	$ 382,105	$ 317,202

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 25, 2024	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Mar. 30, 2024
Property, Plant and Equipment [Line Items]
Total		$ 939,094		$ 939,094		$ 959,177
Less: accumulated depreciation		(638,616)		(638,616)		(647,815)
Property, plant and equipment, net		300,478		300,478		311,362
Depreciation		15,000	$ 13,600	29,600	$ 26,900
Proceeds from sale of property, plant and equipment	$ 19,900			20,551	921
Sale of property	$ 14,100			14,412	$ 444
Land
Property, Plant and Equipment [Line Items]
Total		3,764		3,764		4,130
Building and building improvements
Property, Plant and Equipment [Line Items]
Total		124,264		124,264		124,338
Plant equipment and machinery
Property, Plant and Equipment [Line Items]
Total		227,930		227,930		204,622
Office equipment and information technology
Property, Plant and Equipment [Line Items]
Total		132,845		132,845		129,979
Haemonetics equipment
Property, Plant and Equipment [Line Items]
Total		425,402		425,402		456,414
Construction in progress
Property, Plant and Equipment [Line Items]
Total		$ 24,889		$ 24,889		$ 39,694

LEASES (Details)

LEASES (Details)	6 Months Ended
	Sep. 28, 2024
Leases [Abstract]
Operating lease, revenue, as a percentage of total net sales	3%

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Apr. 01, 2024
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		$ 10,400
Aggregate amortization expense	$ 14,200	$ 9,400	$ 28,700	$ 19,200
Developed technology | Attune Medical
Finite-Lived Intangible Assets [Line Items]
Acquired intangibles					$ 96,100
Customer-Related Intangible Assets | Attune Medical
Finite-Lived Intangible Assets [Line Items]
Acquired intangibles					7,800
Trade names | Attune Medical
Finite-Lived Intangible Assets [Line Items]
Acquired intangibles					$ 1,900
Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	5 years		5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	15 years		15 years

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Sep. 28, 2024 USD ($)
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	$ 565,082
Purchase accounting adjustments	(19,248)
Acquisitions	69,542
Currency translation	786
Goodwill, carrying amount, ending balance	616,162
Plasma
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	29,043
Purchase accounting adjustments	0
Acquisitions	0
Currency translation	0
Goodwill, carrying amount, ending balance	29,043
Blood Center
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	33,484
Purchase accounting adjustments	0
Acquisitions	0
Currency translation	84
Goodwill, carrying amount, ending balance	33,568
Hospital
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	502,555
Purchase accounting adjustments	(19,248)
Acquisitions	69,542
Currency translation	702
Goodwill, carrying amount, ending balance	$ 553,551

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Mar. 30, 2024
Amortizable:
Gross Carrying Amount	$ 966,979	$ 843,096
Accumulated Amortization	484,517	455,213
Net	482,462	387,883
Non-amortizable:	5,375	18,234
In-process software development
Amortizable:
Non-amortizable:	5,375	4,567
In-process research and development
Amortizable:
Non-amortizable:		13,667
Developed technology
Amortizable:
Gross Carrying Amount	573,745	464,291
Accumulated Amortization	199,048	178,413
Net	374,697	285,878
Customer contracts and related relationships
Amortizable:
Gross Carrying Amount	264,703	255,144
Accumulated Amortization	194,055	190,033
Net	70,648	65,111
Capitalized software
Amortizable:
Gross Carrying Amount	84,783	84,837
Accumulated Amortization	73,160	69,491
Net	11,623	15,346
Patents and other
Amortizable:
Gross Carrying Amount	27,504	24,504
Accumulated Amortization	12,326	11,820
Net	15,178	12,684
Trade names
Amortizable:
Gross Carrying Amount	16,244	14,320
Accumulated Amortization	5,928	5,456
Net	$ 10,316	$ 8,864

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Maturity (Details) $ in Thousands	Sep. 28, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2025	$ 26,135
Fiscal 2026	49,842
Fiscal 2027	47,893
Fiscal 2028	46,121
Fiscal 2029	$ 44,927

NOTES_PAYABLE AND LONG-TERM D_2

NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Mar. 30, 2024
Debt Instrument [Line Items]
Notes payable and current maturities of long-term debt	$ (5,434)	$ (10,229)
Long-term debt	1,219,523	797,564
Convertible notes
Debt Instrument [Line Items]
Debt outstanding	981,513	494,813
Term loan, net of financing fees
Debt Instrument [Line Items]
Debt outstanding	242,511	261,971
Revolving credit facility
Debt Instrument [Line Items]
Debt outstanding	0	50,000
Other borrowings
Debt Instrument [Line Items]
Debt outstanding	$ 933	$ 1,009

NOTES_PAYABLE AND LONG-TERM D_3

NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands			3 Months Ended	6 Months Ended
	May 28, 2024	Apr. 30, 2024	Sep. 28, 2024	Sep. 28, 2024	Sep. 30, 2023	Mar. 30, 2024	Jul. 26, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Gain (loss) on repurchase of debt instrument				$ 12,600,000	$ 0
Proceeds from issuance of convertible notes				700,000,000	0
Capped call transaction, initial strike price (in dollars per share)	$ 117.12
Capped call transaction, initial cap price (in dollars per share)	$ 180.18
Capped call transaction, anti-dilution adjustment (in shares)	5,980
Purchase of capped call related to convertible notes	$ 88,200,000			88,200,000	0
Repayments of Long-term Debt				1,563,000	$ 5,250,000
Debt instrument, percent of principal amount due in years 1-3		2.50%
Debt instrument, percent of principal amount due in year 4		5%
Debt instrument, percent of principal amount due in year 5		7.50%
Consolidated total leverage ratio		4
Consolidated interest coverage ratio		4.5
Fiscal 2026			$ 306,355,000	306,355,000
Convertible notes
Debt Instrument [Line Items]
Debt outstanding			981,513,000	981,513,000		$ 494,813,000
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt, gross			248,400,000	248,400,000
Debt outstanding			$ 242,511,000	$ 242,511,000		261,971,000
Effective interest rate			6.70%	6.70%
Revolving credit facility
Debt Instrument [Line Items]
Debt outstanding			$ 0	$ 0		$ 50,000,000
Uncommitted Operating Lines of Credit
Debt Instrument [Line Items]
Debt outstanding			0	0
Maximum borrowing capacity			19,800,000	19,800,000
Convertible Senior Notes Due 2026 | Convertible notes
Debt Instrument [Line Items]
Face amount of debt								$ 500,000,000
Stated rate (as a percent)								0%
Debt Instrument, Repurchased Face Amount	200,000,000
Debt Instrument, Repurchase Amount	185,500,000
Gain (loss) on extinguishment of debt, before debt issuance cost writeoff	14,500,000
Deferred debt issuance cost, writeoff	1,900,000
Gain (loss) on repurchase of debt instrument	(12,600,000)
Long-term debt, gross			300,000,000	300,000,000
Debt issuance costs, net			2,300,000	2,300,000
Debt outstanding			297,700,000	297,700,000
Interest expense, debt			$ 400,000	$ 1,000,000
Effective interest rate			0.50%	0.50%
Convertible Senior Notes Due 2029 | Convertible notes
Debt Instrument [Line Items]
Face amount of debt	$ 700,000,000
Stated rate (as a percent)	2.50%
Debt issuance costs, net			$ 16,200,000	$ 16,200,000
Debt outstanding			683,800,000	683,800,000
Interest expense, debt			5,200,000	6,900,000
Effective interest rate	3%
Proceeds from issuance of convertible notes	$ 682,800,000
Debt instrument, redemption price, percentage	130%
Debt instrument, redemption price, percentage of principal amount redeemed	98%
Debt instrument, redemption price, percentage of previous closing price	10%
Debt instrument, convertible, conversion rate	8.5385
Debt instrument, convertible, conversion price	$ 117.12
Debt issuance costs, gross	$ 17,200,000
Convertible Senior Notes Due 2029 | Convertible notes | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	130%
Convertible Senior Notes Due 2029 | Convertible notes | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100%
2022 Revised Credit Facilities | Term loan, net of financing fees
Debt Instrument [Line Items]
Face amount of debt							$ 280,000,000
2022 Revised Credit Facilities | Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 420,000,000
2022 Revised Credit Facilities | Revolving credit facility | Minimum
Debt Instrument [Line Items]
Stated rate (as a percent)							1.125%
2022 Revised Credit Facilities | Revolving credit facility | Maximum
Debt Instrument [Line Items]
Stated rate (as a percent)							1.75%
2024 Revised Credit Facilities | Term loan, net of financing fees
Debt Instrument [Line Items]
Face amount of debt		$ 250,000,000
Debt issuance costs, net			5,900,000	5,900,000
Repayments of Long-term Debt		$ 12,500,000
Fiscal 2026			6,300,000	6,300,000
2024 Revised Credit Facilities | Term loan, net of financing fees | Minimum
Debt Instrument [Line Items]
Stated rate (as a percent)		1.125%
Interest rate floor		0%
2024 Revised Credit Facilities | Term loan, net of financing fees | Maximum
Debt Instrument [Line Items]
Stated rate (as a percent)		1.75%
2024 Revised Credit Facilities | Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 750,000,000
Additional debt issuance costs capitalized		$ 5,900,000
2024 Revised Credit Facilities | Revolving credit facility | Minimum
Debt Instrument [Line Items]
Revolving credit facility unused fee percentage		0.125%
2024 Revised Credit Facilities | Revolving credit facility | Maximum
Debt Instrument [Line Items]
Revolving credit facility unused fee percentage		0.25%
Revised Credit Agreement | Unsecured Debt
Debt Instrument [Line Items]
Interest expense			$ 4,900,000	$ 12,000,000

NOTES_PAYABLE AND LONG-TERM D_4

NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details) $ in Thousands	Sep. 28, 2024 USD ($)
Debt Disclosure [Abstract]
Remainder of Fiscal 2025	$ 3,198
Fiscal 2026	306,355
Fiscal 2027	6,312
Fiscal 2028	11,003
Fiscal 2029	17,257
Thereafter	$ 905,246

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Narrative) (Details)				1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 27, 2024 swap	Sep. 26, 2024 swap	Jun. 15, 2023 swap	Sep. 30, 2022 swap	Sep. 28, 2024 USD ($)	Sep. 28, 2024 USD ($)	Apr. 01, 2024 USD ($)	Mar. 30, 2024 USD ($)	Sep. 23, 2022 USD ($)
Derivative [Line Items]
Number of Interest Rate Swaps Remaining | swap	2
Level 2 | Convertible Senior Notes Due 2026
Derivative [Line Items]
Convertible notes, fair value					$ 277,700,000	$ 277,700,000
Level 2 | Convertible Senior Notes Due 2029
Derivative [Line Items]
Convertible notes, fair value					701,700,000	701,700,000
Term loan, net of financing fees
Derivative [Line Items]
Debt outstanding					$ 242,511,000	$ 242,511,000		$ 261,971,000
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US					25.90%	25.90%
Maturity period for foreign currency contracts						1 year
Interest Rate Swap
Derivative [Line Items]
Number of interest rate swaps entered | swap				4
Derivative, percentage of notional value of debt	80%
Derivative, blended fixed interest rate	3.31%
Notional amount					$ 205,800,000	$ 205,800,000			$ 205,800,000
Number Of Interest Rate Swaps Terminated | swap		2	2
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)					0	0
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding					30,800,000	30,800,000		74,000,000
Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months						1,300,000
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding					38,000,000	38,000,000		$ 39,900,000
Attune Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration							$ 25,300,000
Attune Medical | Other Current Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration					8,000,000	8,000,000
Attune Medical | Other Noncurrent Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration					$ 18,300,000	$ 18,300,000

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Schedule of Interest Rate Swaps) (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Mar. 30, 2024	Sep. 23, 2022
Fair Value, Recurring [Member]
Derivative [Line Items]
Derivative Assets	$ 776	$ 3,242
Derivative Liabilities	2,509	931
Interest Rate Swap
Derivative [Line Items]
Notional amount	205,800		$ 205,800
Estimated Fair Value Assets (Liabilities)	(1,037)
Interest Rate Swap | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities	1,781
Interest Rate Swap | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities	1,781
Interest Rate Swap | Other Current Assets | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		1,673
Interest Rate Swap | Other Current Assets | Level 2 | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	744
Interest Rate Swap | Other Noncurrent Assets | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities		62
Interest Rate Swap | Other Noncurrent Assets | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities	0
Interest Rate Swap, 4.08% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 103,600		103,600
Derivative fixed interest rate	3.32%
Estimated Fair Value Assets (Liabilities)	$ (634)
Interest Rate Swap, 4.15% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 102,200		$ 102,200
Derivative fixed interest rate	3.30%
Estimated Fair Value Assets (Liabilities)	$ (403)
Foreign Exchange Contract | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		1,353
Derivative Liabilities	624	395
Foreign Exchange Contract | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	32	154
Derivative Liabilities	104	536
Foreign Exchange Contract | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		1,353
Derivative Liabilities		395
Foreign Exchange Contract | Level 2 | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		154
Foreign Exchange Contract | Other Current Assets | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		1,353
Foreign Exchange Contract | Other Current Assets | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		$ 154
Foreign Exchange Contract | Other Current Assets | Level 2 | Fair Value, Recurring [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	0
Foreign Exchange Contract | Other Current Assets | Level 2 | Fair Value, Recurring [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	$ 32

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Allowance for credit losses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 5,719	$ 5,047	$ 5,695	$ 4,932
Credit loss	179	30	216	181
Write-offs	14	(33)	1	(69)
Ending balance	$ 5,912	$ 5,044	$ 5,912	$ 5,044

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) $ in Thousands	6 Months Ended
	Sep. 28, 2024 USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest and other expense, net
Designated as Hedging Instrument | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	$ (1,263)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	(506)
Amount of Gain Excluded from Effectiveness Testing	506
Designated as Hedging Instrument | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	(2,053)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	36
Amount of Gain Excluded from Effectiveness Testing	0
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Accumulated Other Comprehensive Loss	0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	0
Amount of Gain Excluded from Effectiveness Testing	$ 117

FINANCIAL INSTRUMENTS AND FAI_7

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASURES (Schedules of Derivatives) (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 28, 2024	Mar. 30, 2024
Liabilities
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date	$ 25,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment	300
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	1,034
Fair Value, Recurring [Member]
Assets
Money market funds	155,290	$ 43,073
Derivative Assets	776	3,242
Assets fair value	156,066	46,315
Liabilities
Derivative Liabilities	2,509	931
Liabilities fair value	28,843	931
Fair Value, Recurring [Member] | Level 1
Assets
Money market funds	155,290	43,073
Assets fair value	155,290	43,073
Liabilities
Liabilities fair value	0	0
Fair Value, Recurring [Member] | Level 2
Assets
Money market funds	0	0
Assets fair value	776	3,242
Liabilities
Liabilities fair value	2,509	931
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	26,334	0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Designated as Hedging Instrument
Assets
Derivative Assets		1,353
Liabilities
Derivative Liabilities	624	395
Fair Value, Recurring [Member] | Foreign Exchange Contract | Designated as Hedging Instrument | Level 1
Assets
Derivative Assets		0
Liabilities
Derivative Liabilities	0	0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		1,353
Liabilities
Derivative Liabilities		395
Fair Value, Recurring [Member] | Foreign Exchange Contract | Not Designated as Hedging Instrument
Assets
Derivative Assets	32	154
Liabilities
Derivative Liabilities	104	536
Fair Value, Recurring [Member] | Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		154
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument
Assets
Derivative Assets		1,353
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	0
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument
Assets
Derivative Assets		154
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	32
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		395
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	624
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		536
Fair Value, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	104	536
Fair Value, Recurring [Member] | Interest Rate Swap | Designated as Hedging Instrument
Liabilities
Derivative Liabilities	1,781
Fair Value, Recurring [Member] | Interest Rate Swap | Designated as Hedging Instrument | Level 1
Liabilities
Derivative Liabilities	0
Fair Value, Recurring [Member] | Interest Rate Swap | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	1,781
Fair Value, Recurring [Member] | Interest Rate Swap | Other Current Assets | Not Designated as Hedging Instrument
Assets
Derivative Assets		1,673
Fair Value, Recurring [Member] | Interest Rate Swap | Other Current Assets | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	744
Fair Value, Recurring [Member] | Interest Rate Swap | Other Noncurrent Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		0
Fair Value, Recurring [Member] | Interest Rate Swap | Other Noncurrent Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	1,781
Fair Value, Recurring [Member] | Interest Rate Swap | Other Assets | Not Designated as Hedging Instrument
Assets
Derivative Assets	744	1,735
Fair Value, Recurring [Member] | Interest Rate Swap | Other Assets | Not Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Fair Value, Recurring [Member] | Interest Rate Swap | Other Assets | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	744	1,735
Fair Value, Recurring [Member] | Contingent Consideration
Liabilities
Liabilities fair value	26,334	$ 0
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	26,334
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3 | Revenue-based payment
Liabilities
Liabilities fair value	$ 20,606
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate	6.30%
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3 | Regulatory-based payment
Liabilities
Liabilities fair value	$ 4,735
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate	6.10%
Fair Value, Recurring [Member] | Contingent Consideration | Fair Value, Inputs, Level 3 | Event-based payment
Liabilities
Liabilities fair value	$ 993
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate	5.80%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Sep. 28, 2024	Mar. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Loss contingency, estimate of possible loss		$ 8,700
Payments for legal settlements	$ 8,700
Loss in period		$ 6,800

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Sep. 28, 2024	Jun. 29, 2024	Sep. 30, 2023	Jul. 01, 2023	Sep. 28, 2024
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2024		$ (35,632)			$ (35,632)
Other comprehensive income (loss) before reclassifications					1,538
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)					(470)
Net current period other comprehensive income (loss)	$ 8,103	(7,035)	$ (3,187)	$ 863	1,068
Balance as of September 28, 2024	(34,564)				(34,564)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2024		(38,274)			(38,274)
Other comprehensive income (loss) before reclassifications					4,854
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)					0
Net current period other comprehensive income (loss)					4,854
Balance as of September 28, 2024	(33,420)				(33,420)
Defined Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2024		1,748			1,748
Other comprehensive income (loss) before reclassifications					0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)					0
Net current period other comprehensive income (loss)					0
Balance as of September 28, 2024	1,748				1,748
Net Unrealized Gain (Loss) on Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2024		$ 894			894
Other comprehensive income (loss) before reclassifications					(3,316)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)					(470)
Net current period other comprehensive income (loss)					(3,786)
Balance as of September 28, 2024	$ (2,892)				$ (2,892)

SEGMENT AND ENTERPRISE-WIDE I_3

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 28, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 28, 2024 USD ($) segment	Sep. 30, 2023 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			3
Net revenues in constant currency	$ 345,753	$ 319,063	$ 683,040	$ 630,151
Effect of exchange rates	(242)	(880)	(1,357)	(636)
Net revenues	345,511	318,183	681,683	629,515
Operating income	51,697	35,303	91,453	88,962
Effect of exchange rates	1,312	(3,091)	(37)	(478)
Amortization of acquired intangible assets	12,264	7,222	24,735	14,695
Amortization of fair value inventory step-up	3,739	0	8,978	0
Integration and transaction costs	(882)	(1,784)	(13,205)	(2,899)
Restructuring costs	(4,792)	(86)	9,414	75
Restructuring related costs	1,571	1,947	4,089	4,151
Digital transformation costs	4,858	3,592	11,203	7,297
PCS2 related charges	0	(552)	0	(411)
MDR and IVDR costs	(991)	(1,988)	(2,117)	(3,154)
Litigation-related charges	(320)	(5,449)	(1,075)	(6,507)
Impairment of intangible assets	(2,391)	(10,419)	(2,391)	(10,419)
Gain on sale of property, plant and equipment	0	0	14,134	0
United States
Segment Reporting Information [Line Items]
Net revenues	256,061	236,345	504,963	473,418
Japan
Segment Reporting Information [Line Items]
Net revenues	16,424	15,011	30,129	26,784
Europe
Segment Reporting Information [Line Items]
Net revenues	41,991	38,666	89,216	78,053
Rest of Asia
Segment Reporting Information [Line Items]
Net revenues	25,768	27,735	45,551	49,775
Other
Segment Reporting Information [Line Items]
Net revenues	5,267	426	11,824	1,485
Plasma
Segment Reporting Information [Line Items]
Net revenues in constant currency	138,565	142,643	274,607	282,134
Restructuring related costs	51	74	226	243
Plasma | Plasma
Segment Reporting Information [Line Items]
Net revenues	138,561	142,794	274,471	282,415
Blood Center
Segment Reporting Information [Line Items]
Net revenues in constant currency	68,804	70,470	135,643	139,639
Restructuring related costs	46	28	89	73
Blood Center | Blood Center
Segment Reporting Information [Line Items]
Net revenues	68,528	69,656	134,773	138,862
Apheresis | Blood Center
Segment Reporting Information [Line Items]
Net revenues	54,332	54,973	103,426	104,139
Whole Blood | Blood Center
Segment Reporting Information [Line Items]
Net revenues	14,196	14,683	31,347	34,723
Hospital
Segment Reporting Information [Line Items]
Net revenues in constant currency	138,384	105,950	272,790	208,378
Restructuring related costs	0	98	108	147
Hospital | Hospital
Segment Reporting Information [Line Items]
Net revenues	138,422	105,733	272,439	208,238
Vascular Closure, Hosptial | Hospital
Segment Reporting Information [Line Items]
Net revenues	61,923	38,541	124,967	76,161
Hemostasis Management, Hospital | Hospital
Segment Reporting Information [Line Items]
Net revenues	76,499	67,192	147,472	132,077
Operating Segments
Segment Reporting Information [Line Items]
Operating income	156,600	147,183	298,950	290,107
Operating Segments | Plasma
Segment Reporting Information [Line Items]
Operating income	69,728	78,042	135,565	153,740
Operating Segments | Blood Center
Segment Reporting Information [Line Items]
Operating income	27,167	27,307	49,789	53,590
Operating Segments | Hospital
Segment Reporting Information [Line Items]
Operating income	59,705	41,834	113,596	82,777
Corporate
Segment Reporting Information [Line Items]
Operating income	$ 74,407	$ 75,750	$ 144,387	$ 151,059